The French National Authority for Health (HAS) issues a favorable opinion on the exceptional reimbursement coverage of VisioCyt® Bladder.

VitaDX welcomes the favorable opinion issued by the French National Authority for Health (HAS) on June 5, 2025, regarding the exceptional reimbursement coverage of digitized and artificial intelligence–assisted urinary cytology using the medical device VisioCyt® Bladder for the surveillance of recurrences of non–muscle-invasive bladder tumors (NMIBC).